title: CXCR2 Expression on neutrophils is upregulated during the relapsing phase of ocular Behcet disease.
abstract: OBJECTIVE
  To search for markers of Behcet disease (BD) activity,we measured CXCR1 and CXCR2 levels on the circulating leukocytes of patients suffering from ocular BD.
  
  
  METHODS
  Peripheral blood leukocytes were harvested from healthy volunteers (n = 16) and ocular BD patients (n = 35). The patients consisted of 15 individuals in relapsing phase (6 with prednisolone treatment) and 20 individuals in remission phase (9 with prednisolone treatment). Expression of CXC chemokine receptors (CXCRs) on leukocytes (including lymphocytes, monocytes, neutrophils) was measured using flow cytometry.
  
  
  RESULTS
  Without prednisolone treatment, CXCR2 expression (on both total leukocytes and neutrophils) in relapsing phase was significantly higher than in remission-phase patients or normal individuals. By contrast, no significant difference was detected in the expression of CXCR1 between any ofthe groups. Importantly, low-dose prednisolone therapy reduced CXCR2 expression on neutrophils.
  
  
  CONCLUSIONS
  CXCR2 has a potential role in promot-ing uveitis during ocular attack and might also be a useful marker for disease activity.
authors.affiliation: Department of Ophthalmology Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Hong
authors.initials: H
authors.lastname: Qiao
authors.forename: Koh-Hei
authors.initials: KH
authors.lastname: Sonoda
authors.forename: Akiko
authors.initials: A
authors.lastname: Ariyama
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Kuratomi
authors.forename: Yoh-Ichi
authors.initials: Y
authors.lastname: Kawano
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Ishibashi
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000097:blood* / Q000188:drug therapy; D015415:Biomarkers / Q000378:metabolism; D003078:Colchicine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005434:Flow Cytometry; D006801:Humans; D009504:Neutrophils / Q000378:metabolism*; D011239:Prednisolone / Q000627:therapeutic use; D023062:Receptors, Interleukin-8A / Q000378:metabolism; D023063:Receptors, Interleukin-8B / Q000378:metabolism*; D012008:Recurrence; D015854:Up-Regulation
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B; D011239:Prednisolone; D003078:Colchicine